相关实验视频
Updated: Sep 18, 2025

20:16
Detecting Anastasis In Vivo by CaspaseTracker Biosensor
Published on: February 1, 2018
9.4K
针对分化甲状腺癌的放射性治疗后的二次血液性恶性瘤风险的元分析
Hongyue Su1, Fan Yang1, Zhiyuan Wang1
1Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
International journal of surgery (London, England)
|June 24, 2025
概括
对差异化甲状腺癌 (DTC) 的放射性 (RAI) 治疗可能会增加二次血液恶性瘤的风险,特别是白血病. 然而,低于3.7GBq的RAI剂量似乎可以减轻这种风险,因此需要进一步调查.
科学领域:
- 在瘤学瘤学.
- 核医学是一种核医学.
- 流行病学 流行病学
背景情况:
- 放射性 (RAI) 治疗是对差异化甲状腺癌 (DTC) 的标准治疗方法.
- 有关RAI暴露后可能出现二次原发性恶性瘤的担忧.
- 在DTC患者中RAI和血液恶性瘤之间的关联需要进一步澄清.
研究的目的:
- 评估RAI管理与DTC患者中二次血液恶性瘤的风险之间的关联.
- 调查特定的血液性恶性瘤亚型和RAI剂量对风险的影响.
主要方法:
- 进行了系统的文献综述和元分析.
- 数据来源于PubMed和Web of Science,遵循PRISMA的指导方针.
- 包括包括包括586,260名DTC患者的17项研究.
主要成果:
- RAI治疗与二次血液性恶性瘤的风险增加有关 (RR=1.25,p<0.0001).
- 白血病的风险显著增加 (RR=1.52,p=0.03).
- 低于3.7 GBq的RAI剂量与降低的风险有关 (RR=0.39,p=0.002).
结论:
- 对DTC的RAI治疗可能会增加二次血液性恶性瘤的风险,特别是白血病.
- 较低的RAI剂量 (<3.7GBq) 可能不会增加这种风险.
- 建议进行进一步的大规模前性研究来证实这些发现.
相关概念视频
Biological Effects of Radiation
16.1K
All radioactive nuclides emit high-energy particles or electromagnetic waves. When this radiation encounters living cells, it can cause heating, break chemical bonds, or ionize molecules. The most serious biological damage results when these radioactive emissions fragment or ionize molecules. For example, α and β particles emitted from nuclear decay reactions possess much higher energies than ordinary chemical bond energies. When these particles strike and penetrate matter, they...
16.1K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
184
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
184
Hazard Ratio
261
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
261
Cancer Survival Analysis
458
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
458

